On June 8, Chengdu Olymvax Biopharmaceuticals Inc. was successfully listed on the Science and Technology Venture Board of Shanghai Stock Exchange. OLYMVAX (688319.SH) issued 40,530,000 shares at a price of RMB 9.88 per share, raising a total of RMB with a total share capital of 405,265,000 shares after the issuance.
Founded in 2009, OLYMVAX is a high-tech bio-pharmaceutical enterprise specializing in the R&D, production and sales of human vaccines. The Company is committed to providing domestic and foreign consumers with innovative human vaccine products that are safe, effective and of excellent quality, with huge market potential in the future.
After years of technical accumulation, the Company has mastered six core technologies, including polysaccharide-protein binding technology, genetic engineering technology, peptide vaccine technology, separation and purification technology, high-density bacterial culture technology, and detoxification control technology. For the core technologies, the Company has been awarded a number of invention patents, and applied them to the development and industrialization of multivalent vaccines and innovative vaccines.
At present, OLYMVAX has marketed three vaccine products, including Tetanus Vaccine, Adsorbed, Hib Conjugate Vaccine and AC Conjugate Vaccine, and it is developing five Class 1 innovative vaccines and five multivalent vaccines with broad market.
The funds raised from the IPO are mainly used for the clinical research project of vaccines and the industrialization project of Recombinant Staphylococcus Aureus Vaccine, AC-Hib Combined Vaccine and Pneumonia Vaccine. The projects invested by the raised funds are focused on the Company’s main business and core technologies, which are strategically selected by the Company according to the future development plan, with the purpose of comprehensively enhancing the existing main business and product development capabilities of the Company.
Mr. Fan Shaowen, Chairman and General Manager of OLYMVAX, pointed out that the listing of OLYMVAX on the Science and Technology Innovation Board was an important milestone in the company development history and the starting point for the Company to embark on a new journey. As the first private enterprise producing adsorbent tetanus vaccine in China, OLYMVAX will shoulder the sacred mission of providing safer, high-quality and efficient vaccines for human health. With a strong belief in “honesty, dedication, innovation and transcendence”, OLYMVAX makes more innovations and improvements by the world’s advanced technology and first-class management concept, and strives to become an internationally renowned and domestically leading vaccine supplier.
